Clinical Evaluation Of Endostar Combined With Intraperitoneal Hyperthermia Chemotherapy In The Treatment Of Malignant Intraperitoneal Effusion

Objective:To observe the short-term efficacy and safety of anti-vascular drugs(Endosulfan)and chemotherapy drugs(Cisplatin)in treating malignant tumours complicated with ascites and their influence on immune indexes.Methods:Eighty-three cases of malignant tumours complicated with malignant ascites in the third People’s Hospital of Hubei Province were collected and randomly divided into two groups:Endostar combined with cisplatin intraperitoneal hyperthermia perfusion group(ex-perimental group),and cisplatin intraperitoneal hyperthermia perfusion group(control group)—baseline data collection of two groups of patients.The experimental group was given Endostar 60mg+Cisplatin 50mg/m~2,while the control group was assigned Cisplatin 50mg/m~2,both of which were taken on the 1st,4th,and 7th day after the treatment.21 days is a course of treatment.After treatment,the two groups’objective remission rate,quality of life score,serum T lymphocyte count,and toxic and side effects were compared before and after treat-ment.Conclusions:Before treatment,the baseline data of the two groups were the same(P>0.05).The objective remission rates(ORR)of Endostar combined with cisplatin intraperitoneal hy-perthermia perfusion group(37 cases)and cisplatin intraperitoneal hyperthermia perfusion group(46 patients)were 91.89%and 78.26%(P<0.05).The improvement rate of the KPS score in the experimental group was 94.5%and 71.7%(P<0.05).The experimental group’s CD3+CD4+T lymphocyte count and CD4+/CD8+ratio were significantly enhanced before and after treatment.The probability of all kinds of adverse reactions in the treatment process of the two groups was comparable(P>0.05),with a low incidence of grade III-IV adverse reactions and no treatment-related deaths in the entire experiment.In contrast,the CD8+T lymphocyte count was significantly decreased(P<0.05),while the above indexes in the con-trol group were not relieved considerably(P>0.05).The level of T lymphocyte count in the serum of the two groups after treatment was further compared intuitively,and the difference between the two groups was noticeable(P<0.05).Results:Endostar combined with cisplatin intraperitoneal hyperthermic perfusion for treating malignant ascites has good short-term efficacy and safety and can improve the immune func-tion of patients to a certain extent,which is conducive to the whole-body antitumor.Patients can tolerate it,satisfaction is reasonable,and adverse reactions will not increase.